At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 307 enrolled
Drug / intervention
Veliparib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Veliparib, Placebo, and 1 other intervention for Brain Metastases From Non-small Cell Lung Cancer. Completed, enrolled 307 participants.
Detailed Summary
The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartOct 2012
Primary CompletionJan 2015
TodayJul 2026
First PostedAug 6, 2012
Enrollment StartOct 19, 2012
Primary CompletionJan 22, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.9 years ago
Interventions
Veliparibdrug
Veliparib capsules for oral administration
Placebodrug
Placebo to veliparib capsules for oral administration
Whole brain radiation therapyradiation
30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays